Business Description
Nuvectis Pharma Inc
NAICS : 541714
SIC : 2833
ISIN : US67080T1088
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.64 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate | 9.16 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 32.84 | |||||
9-Day RSI | 34.99 | |||||
14-Day RSI | 38.09 | |||||
6-1 Month Momentum % | 22.59 | |||||
12-1 Month Momentum % | -3.08 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.74 | |||||
Quick Ratio | 2.74 | |||||
Cash Ratio | 2.72 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -9.23 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -145.83 | |||||
ROA % | -100.11 | |||||
ROIC % | -611.91 | |||||
ROCE % | -152.53 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 8.7 | |||||
Price-to-Tangible-Book | 8.69 | |||||
EV-to-EBIT | -3.96 | |||||
EV-to-Forward-EBIT | -3.55 | |||||
EV-to-EBITDA | -3.96 | |||||
EV-to-Forward-EBITDA | -3.55 | |||||
EV-to-FCF | -5.88 | |||||
Price-to-Net-Current-Asset-Value | 8.69 | |||||
Price-to-Net-Cash | 8.84 | |||||
Earnings Yield (Greenblatt) % | -25.25 | |||||
FCF Yield % | -14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NVCT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Nuvectis Pharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -1.16 | ||
Beta | 0 | ||
Volatility % | 66.54 | ||
14-Day RSI | 38.09 | ||
14-Day ATR ($) | 0.903965 | ||
20-Day SMA ($) | 6.813 | ||
12-1 Month Momentum % | -3.08 | ||
52-Week Range ($) | 4.6106 - 12.1 | ||
Shares Outstanding (Mil) | 19.32 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Nuvectis Pharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Nuvectis Pharma Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Nuvectis Pharma Inc Frequently Asked Questions
What is Nuvectis Pharma Inc(NVCT)'s stock price today?
When is next earnings date of Nuvectis Pharma Inc(NVCT)?
Does Nuvectis Pharma Inc(NVCT) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |